Clinical Trial Update: A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia [Phase 2]

View source ↗

Summary

Long-term open-label Phase 2 trial evaluating ML-007C-MA in adults with schizophrenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ML-007C-MA

Snippet

Sponsor: MapLight Therapeutics | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING